Work

Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.4_suppl.558

Authors: Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, Ludwig-Maximilians-Universität München, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Azienda Ospedaliera Universitaria Pisana, University of Pisa

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2913237284

Cites:

Cited by: 1

Related to: 10